- Book
- September 2010
- 544 Pages
- Book
- May 2022
- 1040 Pages
- Book
- September 2023
- 272 Pages
- Book
- September 2023
- 272 Pages
- Book
- May 2022
- 3296 Pages
- Book
- May 2022
- 1040 Pages
- Book
- December 2019
- 560 Pages
- Book
- December 2019
- 560 Pages
- Book
- April 2019
- 816 Pages
- Book
- March 2019
- 480 Pages
- Book
- September 2016
- 680 Pages
- Book
- April 2012
- 1272 Pages
- Book
- November 2008
- 3712 Pages
- Book
- June 2021
North America
- Book
- August 2020
North America
- Book
- December 2018
North America
- Book
- February 2018
North America

The Irritable Bowel Syndrome (IBS) market is a subset of the Gastroenterology market. IBS is a chronic disorder of the digestive system that affects the large intestine. Symptoms include abdominal pain, bloating, constipation, and diarrhea. Treatment options include dietary changes, medications, and lifestyle modifications.
The IBS market is expected to grow due to increasing prevalence of the disorder, rising awareness of IBS, and the availability of new treatments. Additionally, the increasing demand for better diagnosis and treatment of IBS is expected to drive the market.
Some companies in the IBS market include Allergan, AstraZeneca, GlaxoSmithKline, Ironwood Pharmaceuticals, Novartis, Pfizer, Salix Pharmaceuticals, Shire, Sucampo Pharmaceuticals, and Takeda Pharmaceuticals. Show Less Read more